Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

457 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Study design and rationale for ELPIS: A phase I/IIb randomized pilot study of allogeneic human mesenchymal stem cell injection in patients with hypoplastic left heart syndrome.
Kaushal S, Wehman B, Pietris N, Naughton C, Bentzen SM, Bigham G, Mishra R, Sharma S, Vricella L, Everett AD, Deatrick KB, Huang S, Mehta H, Ravekes WA, Hibino N, Difede DL, Khan A, Hare JM. Kaushal S, et al. Among authors: bentzen sm. Am Heart J. 2017 Oct;192:48-56. doi: 10.1016/j.ahj.2017.06.009. Epub 2017 Jun 27. Am Heart J. 2017. PMID: 28938963 Clinical Trial.
Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer.
Vyfhuis MAL, Bhooshan N, Molitoris J, Bentzen SM, Feliciano J, Edelman M, Burrows WM, Nichols EM, Suntharalingam M, Donahue J, Nagib M, Carr SR, Friedberg J, Badiyan S, Simone CB 2nd, Feigenberg SJ, Mohindra P. Vyfhuis MAL, et al. Among authors: bentzen sm. Lung Cancer. 2017 Dec;114:44-49. doi: 10.1016/j.lungcan.2017.10.016. Epub 2017 Nov 2. Lung Cancer. 2017. PMID: 29173764
Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.
Vyfhuis MAL, Bhooshan N, Burrows WM, Turner M, Suntharalingam M, Donahue J, Nichols EM, Feliciano J, Bentzen SM, Badiyan S, Carr SR, Friedberg J, Simone CB 2nd, Edelman MJ, Feigenberg SJ, Mohindra P. Vyfhuis MAL, et al. Among authors: bentzen sm. Adv Radiat Oncol. 2017 Jul 31;2(3):259-269. doi: 10.1016/j.adro.2017.07.009. eCollection 2017 Jul-Sep. Adv Radiat Oncol. 2017. PMID: 29114590 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 34701074
Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
Scilla KA, Bentzen SM, Lam VK, Mohindra P, Nichols EM, Vyfhuis MA, Bhooshan N, Feigenberg SJ, Edelman MJ, Feliciano JL. Scilla KA, et al. Among authors: bentzen sm. Oncologist. 2017 Jun;22(6):737-742. doi: 10.1634/theoncologist.2016-0443. Epub 2017 May 22. Oncologist. 2017. PMID: 28533476 Free PMC article.
Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non-small-cell Lung Cancer Treated With Curative Intent.
Rice SR, Vyfhuis MAL, Scilla KA, Burrows WM, Bhooshan N, Suntharalingam M, Edelman MJ, Feliciano J, Badiyan SN, Simone CB 2nd, Bentzen SM, Feigenberg SJ, Mohindra P. Rice SR, et al. Among authors: bentzen sm. Clin Lung Cancer. 2020 May;21(3):e130-e141. doi: 10.1016/j.cllc.2019.08.009. Epub 2019 Sep 18. Clin Lung Cancer. 2020. PMID: 31708388
457 results